clinical trial · NCT06264180
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Replimune, Inc.·phase3·recruiting·n = 400
Advanced MelanomaVusolimogene OderparepvecNivolumabNivolumab + RelatlimabPembrolizumabSingle-agent chemotherapy
brief summary
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
started
Jul 11, 2024
primary completion
Jan 1, 2029
completion
Aug 31, 2034
last updated
Mar 13, 2026
official title
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol